A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
Key Inclusion Criteria
Key Exclusion Criteria
Other protocol-defined inclusion/exclusion criteria may apply at the end.
CABA, Buenos Aires 1280, Argentina
CABA, Buenos Aires 1407, Argentina
CABA, Buenos Aires 1426, Argentina
CABA, Buenos Aires C1056ABI, Argentina
San Miguel Tucuman, Tucumán Province T4000IFL, Argentina
Caba, C1426, Argentina
Capital Federal, C1023AAB, Argentina
Chemside, Queensland 4032, Australia
Sao Jose Rio Preto, São Paulo 15015-750, Brazil
Sao Jose Rio Preto, São Paulo 15090 000, Brazil
Xian, Shanxi 710061, China
CZE, 110 00, Czechia
Muehldorf Am Inn, Bavaria 84453, Germany
Weiden in Der Oberpfalz, Bavaria 92637, Germany
Saint Ingbert, Saarland 66386, Germany
Hyderabad, Andhra Pradesh 500033, India
Kahoku-gun, Ishikawa-ken 920-0293, Japan
Miyhazaki, Miyazaki 8802102, Japan
Bunkyo Ku, Tokyo 1138431, Japan
Chuo Ku, Tokyo 104-8560, Japan
Chuo-ku, Tokyo 1030027, Japan
Itabashi-ku, Tokyo 1738610, Japan
Shinagawa-ku, Tokyo 1428666, Japan
Toshima-ku, Tokyo 171-0014, Japan
Culiacan Sinaloa, 80230, Mexico
Sochy, 354002, Russia
Bundang Gu, Gyeonggi-do 13620, South Korea
Santiago Compostela, A Coruna 15706, Spain
Bromwich, B71 4HJ, United Kingdom
Tyne and Wear, NE29 8NH, United Kingdom
Wiltshire, SN15 2SB, United Kingdom